4D Molecular Therapeutics (FDMT) Prepaid Assets (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Prepaid Assets of $14.5 million for Q1 2026, up 30.04% year-over-year from $11.1 million in Q1 2025, and up 38.1% quarter-over-quarter from $10.5 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Prepaid Assets (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Prepaid Assets for 8 consecutive years, with $14.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 30.04% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $14.5 million (up 30.04% YoY), while the FY2025 annual figure was $10.5 million, up 4.22% from the prior year.
- Prepaid Assets climbed to $14.5 million in Q1 2026 per FDMT's latest filing, from $10.5 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $14.5 million in Q1 2026 and bottomed at $4.8 million in Q3 2022.
- Historically, Prepaid Assets has averaged $8.7 million across 5 years, with a median of $8.6 million in 2023.
- On a YoY basis, Prepaid Assets climbed as much as 87.8% in 2022 and fell as far as 17.73% in 2022.
- 4D Molecular Therapeutics' Prepaid Assets stood at $7.0 million in 2022, then grew by 20.11% to $8.4 million in 2023, then advanced by 20.33% to $10.1 million in 2024, then advanced by 4.22% to $10.5 million in 2025, then surged by 38.1% to $14.5 million in 2026.
- Business Quant data shows FDMT's Prepaid Assets at $14.5 million in Q1 2026, $10.5 million in Q4 2025, and $7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.01 Mn |
| Mar 31, 2026 | 14.47 Mn |
| Dec 31, 2025 | 10.48 Mn |
| Sep 30, 2025 | 7.31 Mn |
| Jun 30, 2025 | 10.06 Mn |
| Mar 31, 2025 | 11.13 Mn |
| Dec 31, 2024 | 10.06 Mn |
| Sep 30, 2024 | 8.87 Mn |
| Jun 30, 2024 | 10.69 Mn |
| Mar 31, 2024 | 9.68 Mn |
| Dec 31, 2023 | 8.36 Mn |
| Sep 30, 2023 | 8.58 Mn |
| Jun 30, 2023 | 7.43 Mn |
| Mar 31, 2023 | 6.59 Mn |
| Dec 31, 2022 | 6.96 Mn |
| Sep 30, 2022 | 4.76 Mn |
| Jun 30, 2022 | 5.44 Mn |
| Mar 31, 2022 | 6.89 Mn |
| Dec 31, 2021 | 8.46 Mn |
| Sep 30, 2021 | 3.27 Mn |